Ask about this productRelated genes to: IARS2 antibody
- Gene:
- IARS2 NIH gene
- Name:
- isoleucyl-tRNA synthetase 2, mitochondrial
- Previous symbol:
- -
- Synonyms:
- FLJ10326
- Chromosome:
- 1q41
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-09
- Date modifiied:
- 2014-11-19
Related products to: IARS2 antibody
Related articles to: IARS2 antibody
- Ovarian cancer (OC) remains one of the most lethal gynecological cancers worldwide. Despite advances in diagnosis, OC is mostly detected at late stages due to undefined symptoms. Therefore, identifying feasible, reliable, non-invasive biomarkers for early detection and disease stratification of OC is crucial. Tumor-educated platelets (TEPs) have emerged as a promising source for liquid biopsy, harboring oncogenic mRNA signatures that reflect the tumor microenvironment. In this study, we investigated TEP-mRNAs to identify stage-specific biomarkers for OC diagnosis and prognosis, while uncovering disease progression mechanisms and potential therapeutic targets. - Source: PubMed
Publication date: 2026/05/08
Gahin Shaimaa GamalIbrahim Mostafa SBadr Eman - Isoleucyl-tRNA synthetase 2 (IARS2) is a mitochondrial isoleucine-tRNA synthetase of the class I aminoacyl-tRNA synthetase family, and its role in cervical cancer remains poorly defined. Here, we report that IARS2 promotes cervical cancer cell proliferation and survival through regulation of the Rag GTPases and mTORC1. Elevated IARS2 expression was associated with poorer overall survival in patients with cervical cancer. Silencing of IARS2 significantly reduced cell viability and induced apoptosis in cervical cancer cells. Mechanistically, IARS2 inhibited mTOR degradation and sustained activation of the mTOR–eIF4E axis, thereby supporting cell proliferation. The amino acid–binding pocket of IARS2 was essential for these regulatory effects. Moreover, immunoprecipitation assays revealed that IARS2 interacted with Rag GTPases, particularly RagB and RagD. Together, these findings suggest that IARS2 may function as an amino acid sensor within the Rag–mTORC1 complex and highlight IARS2 as a potential therapeutic target in cervical cancer. - Source: PubMed
Publication date: 2026/03/02
Bi YuxinYe YuqinWu XufengCao HuangMa Quanfu - Our previous work established the AD-BXD mouse panel as an innovative model for studying the genetic complexity and heterogeneity underlying Alzheimer's disease (AD). In this study, we leveraged this model and proteomics approach to identify protein signatures linked to cognitive resilience in AD. - Source: PubMed
Chen YuStevenson Tamara KCao YidingFish Lauren ARobbins Julia EMerrihew Gennifer EPark JeaHohman Timothy JMacCoss Michael JKaczorowski Catherine C
- Source: PubMed
- Isoleucyl-tRNA synthetase 2 (IARS2), originally regarded as an enzyme ligating isoleucine to the corresponding tRNA, has been identified as an oncogene recently. However, its function in pancreatic ductal adenocarcinoma (PDAC) remains to be discovered. Here we explored the biological role of IARS2 in PDAC. Up-regulated IARS2 was found in PDAC tissues and cell lines. Kaplan-Meier survival analysis indicated a worse prognosis in patients with high IARS2 expression. CCK-8, EdU, and colony formation assays showed IARS2 overexpression enhanced PDAC proliferation, which was reduced by IARS2 knockdown. Meanwhile, IARS2 down-regulation inhibited PDAC metastasis by impeding epithelial-mesenchymal transition. These results were also supported by subcutaneous xenograft and metastasis assays . To figure out underlying mechanisms, differential and enrichment analyses were conducted and the WNT signaling pathway was discovered. Our results demonstrated that there was no significant relationship between the WNT signaling pathway key factor CTNNB1 and IARS2 at the transcription level. However, cycloheximide assays showed that IARS2 reduced the β-catenin degradation rate. IARS2 inhibited the phosphorylation of β-catenin at the Ser33/37 site and regulated downstream targets of WNT signaling including c-MYC, c-JUN, and MMP7. The enhancement of proliferation and metastasis caused by IARS2 could be reversed by MSAB, an agent that promotes β-catenin degradation. In summary, IARS2 facilitates PDAC proliferation and metastasis by stabilizing β-catenin, which leads to WNT/β-catenin activation. IARS2 serves as an underlying prognosis marker and a potential therapeutic target for PDAC. - Source: PubMed
Publication date: 2024/07/24
Jin YixunHuang XinyangWang ZhuoxinKouken BerikWang QiWang Lifu